|
Distal aortic dissection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Of the 29 individuals diagnosed with the PRKG1 mutation, 12 (41.3%) had TBAD (50% male, TBAD median age: 31 years [range, 16-58 years], median follow-up: 6 years [range, 3-15 years] after TBAD).
|
30871887 |
2019 |
|
Cardiomyopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
|
31337673 |
2019 |
|
Neointimal hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Translocator protein 18 kDa ligand alleviates neointimal hyperplasia in the diabetic rat artery injury model via activating PKG.
|
30738868 |
2019 |
|
Heart failure with preserved ejection fraction [HFpEF]
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the reduced expression of eNOS and the PKG-1 protein and the cGMP content in the aortas of HFpEF pigs were significantly restored after 9 weeks of dapagliflozin treatment.
|
31429767 |
2019 |
|
Blood Coagulation Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The diagnostic performance of PTr-CGK to predict coagulopathy was established by analysis of receiver operating characteristic curves.
|
29707780 |
2018 |
|
Systemic Scleroderma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PKG1 and 2 are upregulated in SSc in a transforming growth factor-β1 (TGFβ1)-dependent manner, as an attempt to compensate for the decreased signalling through the sGC-cGMP-PKG pathway.
|
29311148 |
2018 |
|
Altitude Hypoxia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present study, a novel pattern of upregulated miRNAs and their associated pathways were constructed, including proteoglycans in cancer, spliceosome, gluamatergic synapse, glycolysis/gluconeogenesis, Foxo, cGMP‑PKG and p53 signaling pathways, which may provide novel targets for diagnosing and understanding the mechanism of high altitude hypoxia‑induced disease.
|
30365091 |
2018 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Using selective inhibitors of either PKG or cysteine proteases to separately inhibit the sequential steps in membrane perforation, combined with video microscopy, electron tomography, electron energy loss spectroscopy, and soft X-ray tomography of mature intracellular <i>Plasmodium falciparum</i> parasites, we resolve intermediate steps in egress.
|
28292906 |
2017 |
|
Hyperalgesia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
After intrathecal administration of L-NAME, ODQ and KT5823, effects of HBO on relieving hyperalgesia in rats were reversed (P < 0.05 vs. HBO), and expression of PKG1 mRNA and protein decreased in the spinal dorsal horn of the animals (P < 0.05 vs. HBO).
|
28470432 |
2017 |
|
Thrombocytopenia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here we investigated whether or not PKA/PKG activation could attenuate caspase-dependent apoptosis induced by the anti-cancer drugs ABT-737 (the precursor of navitoclax) and thymoquinone (TQ), thereby potentially limiting chemotherapy-induced thrombocytopenia.
|
28661475 |
2017 |
|
Neuromuscular inhibition
|
0.010 |
Biomarker
|
disease |
BEFREE |
In colonic smooth muscle from rabbit, mouse, and human, l-cysteine, substrate of cystathionine-γ-lyase (CSE), or NaHS, an H<sub>2</sub>S donor, inhibited phosphodiesterase 5 (PDE5) activity and augmented the increase in cGMP levels, IP<sub>3</sub> receptor phosphorylation at Ser<sup>1756</sup> (measured as a proxy for PKG activation), and muscle relaxation in response to NO donor <i>S-</i>nitrosoglutathione (GSNO), suggesting augmentation of cGMP/PKG pathway by H<sub>2</sub>S.
|
28705807 |
2017 |
|
Inflammatory pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cyclic GMP-dependent protein kinase 1 (PKG1) mediates presynaptic nociceptive long-term potentiation (LTP) in the spinal cord and contributes to inflammatory pain in rodents but the present study revealed opposite effects in the context of neuropathic pain.
|
27978504 |
2017 |
|
Maturity onset diabetes mellitus in young
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective analysis of data on 37 CGK-MODY patients consisting of 21 girls and 16 boys of ages 1.9-20.1 (mean 12.5±5.2) years, treated in our centre in the time period between 2002 and 2013.
|
28663157 |
2017 |
|
Alzheimer Disease, Late Onset
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the application to the real datasets, DCL identified rs6784615, located on the NISCH gene, and rs10824310, located on the PRKG1 gene, as direct causes of late onset Alzheimer's disease (LOAD) development.
|
28363452 |
2017 |
|
Forgetful
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA/PKG-dependent neuro-inflammatory and apoptotic pathways.
|
28935920 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that PDE10 can be targeted for cancer therapy or prevention whereby inhibition results in cGMP elevation and PKG activation to reduce β-catenin-mediated transcription of survival proteins leading to the selective apoptosis of cancer cells.
|
26713600 |
2016 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here we report that the concentration range by which the highly specific PDE10 inhibitor, Pf-2545920 (MP-10), inhibits colon tumor cell growth parallels the concentration range required to increase cGMP and cAMP levels, and activates PKG and PKA, respectively.
|
26713600 |
2016 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our data identify this cGMP-cGKI pathway as the link between sildenafil usage and increased melanoma risk.
|
26971999 |
2016 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that PDE10 can be targeted for cancer therapy or prevention whereby inhibition results in cGMP elevation and PKG activation to reduce β-catenin-mediated transcription of survival proteins leading to the selective apoptosis of cancer cells.
|
26713600 |
2016 |
|
Arrhythmogenic Right Ventricular Dysplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have described a reduction of plakoglobin (PKG) protein at the level of intercalated disks as the hallmark of ARVC.
|
24832006 |
2015 |
|
acute aortic dissection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections.
|
23910461 |
2013 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of the NO/cGMP/PKG pathway reduced migration and invasion of human breast cancer cells, whereas PKG activation enhanced their motility and invasion. siRNA-mediated knockdown of endogenous CaD had pro-migratory and pro-invasive effects in human breast cancer cells.
|
23418348 |
2013 |
|
Cardiovascular Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We found that PKG-1α enzyme activity was attenuated by exposure to the NO donor, spermine NONOate, hydrogen peroxide, and peroxynitrite but not by superoxide, suggesting that the attenuation of PKG-1α activity may be an under-appreciated mechanism underlying the development of endothelial dysfunction in a number of cardiovascular diseases.
|
21600289 |
2011 |
|
Endothelial dysfunction
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We found that PKG-1α enzyme activity was attenuated by exposure to the NO donor, spermine NONOate, hydrogen peroxide, and peroxynitrite but not by superoxide, suggesting that the attenuation of PKG-1α activity may be an under-appreciated mechanism underlying the development of endothelial dysfunction in a number of cardiovascular diseases.
|
21600289 |
2011 |
|
Malaria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Discovery of essential roles for the P. falciparum PKG in both asexual and sexual development demonstrates that cGMP signaling is a key regulator of both of these crucial life cycle phases and defines this molecule as an exciting potential drug target for both therapeutic and transmission blocking action against malaria.
|
19915077 |
2010 |